Literature DB >> 11342349

Acute pancreatitis associated with interferon alpha therapy for chronic myelogenous leukemia.

N M Tannir1, M Talpaz, H Ghazal, S Proothi, H M Kantarjian.   

Abstract

Acute pancreatitis related to interferon alpha therapy is very rare. We report two patients with chronic myelogenous leukemia (CML) who developed acute pancreatitis following treatment with interferon alpha. A review of the literature on the association of pancreatitis and interferon alpha is provided. Possible pathophysiologic mechanisms are also discussed.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11342349     DOI： 10.3109/10428190009113396

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


  5 in total

1.  Type I interferons mediate pancreatic toxicities of PERK inhibition.

Authors:  Qiujing Yu; Bin Zhao; Jun Gui; Kanstantsin V Katlinski; Angela Brice; Yan Gao; ChangHong Li; Jake A Kushner; Constantinos Koumenis; J Alan Diehl; Serge Y Fuchs
Journal:  Proc Natl Acad Sci U S A       Date:  2015-12-01       Impact factor: 11.205

2.  Acute Pancreatitis Associated with Pegylated Interferon and Ribavirin Treatment of Chronic Hepatitis C, Genotype 1b with High Viral Load.

Authors:  Kenji Ando; Soo Ryang Kim; Susumu Imoto; Taisuke Nakajima; Keiji Mita; Katsumi Fukuda; Miyuki Taniguchi; Noriko Sasase; Akira Muramatsu; Toshiyuki Matsuoka; Masatoshi Kudo; Yoshitake Hayashi
Journal:  Case Rep Gastroenterol       Date:  2009-11-21

3.  Acute pancreatitis associated with interferon and ribavirin therapy in patients with chronic hepatitis C.

Authors:  Swati Chaudhari; James Park; Bhupinderjit S Anand; Neville R Pimstone; Douglas T Dieterich; Steven Batash; Edmund J Bini
Journal:  Dig Dis Sci       Date:  2004-06       Impact factor: 3.199

Review 4.  Drug-induced pancreatitis : incidence, management and prevention.

Authors:  Anil R Balani; James H Grendell
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

5.  Drug induced pancreatitis: A systematic review of case reports to determine potential drug associations.

Authors:  Dianna Wolfe; Salmaan Kanji; Fatemeh Yazdi; Pauline Barbeau; Danielle Rice; Andrew Beck; Claire Butler; Leila Esmaeilisaraji; Becky Skidmore; David Moher; Brian Hutton
Journal:  PLoS One       Date:  2020-04-17       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.